Jay Luly, Enanta CEO (via YouTube)

As Big Phar­ma cir­cles RSV wag­ons, biotech re­ports mid-stage flop for its an­tivi­ral

A Phase IIb flop is cast­ing a shad­ow on one biotech’s ef­forts to take on RSV, a no­to­ri­ous­ly tough field strewn with Big Phar­ma ri­vals.

Enan­ta Phar­ma­ceu­ti­cals was plain about the topline da­ta from the RSVP tri­al, which en­rolled oth­er­wise healthy adults with com­mu­ni­ty-ac­quired res­pi­ra­to­ry syn­cy­tial virus. Its drug, EDP-938, met nei­ther the pri­ma­ry end­point of re­duc­tion in to­tal symp­tom score com­pared to place­bo, nor the sec­ondary an­tivi­ral end­points.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.